167 related articles for article (PubMed ID: 23127806)
1. Randomized, double-blind, placebo-controlled trial of polyethylene glycol (MiraLAX®) for urinary urge symptoms.
Bush NC; Shah A; Barber T; Yang M; Bernstein I; Snodgrass W
J Pediatr Urol; 2013 Oct; 9(5):597-604. PubMed ID: 23127806
[TBL] [Abstract][Full Text] [Related]
2. Cochrane Review: Osmotic and stimulant laxatives for the management of childhood constipation (Review).
Gordon M; Naidoo K; Akobeng AK; Thomas AG
Evid Based Child Health; 2013 Jan; 8(1):57-109. PubMed ID: 23878124
[TBL] [Abstract][Full Text] [Related]
3. Superiority of fesoterodine 8 mg vs 4 mg in reducing urgency urinary incontinence episodes in patients with overactive bladder: results of the randomised, double-blind, placebo-controlled EIGHT trial.
Chapple C; Schneider T; Haab F; Sun F; Whelan L; Scholfield D; Dragon E; Mangan E
BJU Int; 2014 Sep; 114(3):418-26. PubMed ID: 24552358
[TBL] [Abstract][Full Text] [Related]
4. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial.
Chapple C; Sievert KD; MacDiarmid S; Khullar V; Radziszewski P; Nardo C; Thompson C; Zhou J; Haag-Molkenteller C
Eur Urol; 2013 Aug; 64(2):249-56. PubMed ID: 23608668
[TBL] [Abstract][Full Text] [Related]
5. A comparison of polyethylene glycol laxative and placebo for relief of constipation from constipating medications.
DiPalma JA; Cleveland MB; McGowan J; Herrera JL
South Med J; 2007 Nov; 100(11):1085-90. PubMed ID: 17984738
[TBL] [Abstract][Full Text] [Related]
6. Effects of tolterodine ER on patient-reported outcomes in sexually active women with overactive bladder and urgency urinary incontinence.
Rogers RG; Bachmann G; Scarpero H; Jumadilova Z; Sun F; Morrow JD; Guan Z; Bavendam T
Curr Med Res Opin; 2009 Sep; 25(9):2159-65. PubMed ID: 19601704
[TBL] [Abstract][Full Text] [Related]
7. A prospective, double-blind, randomized, placebo-controlled trial comparing the efficacy of polyethylene glycol versus polyethylene glycol combined with topical diltiazem for treating anal fissure in children.
Alshehri A; Barghouthi R; Albanyan S; Alayed M; Alsubaie H; Alhayyan R; Alzahem A; Altokhais T; Albassam A; Aljazaeri A
J Pediatr Surg; 2020 Oct; 55(10):2017-2021. PubMed ID: 32057442
[TBL] [Abstract][Full Text] [Related]
8. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial.
Kaplan SA; Roehrborn CG; Rovner ES; Carlsson M; Bavendam T; Guan Z
JAMA; 2006 Nov; 296(19):2319-28. PubMed ID: 17105794
[TBL] [Abstract][Full Text] [Related]
9. Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial.
Herschorn S; Swift S; Guan Z; Carlsson M; Morrow JD; Brodsky M; Gong J
BJU Int; 2010 Jan; 105(1):58-66. PubMed ID: 20132103
[TBL] [Abstract][Full Text] [Related]
10. Osmotic and stimulant laxatives for the management of childhood constipation.
Gordon M; Naidoo K; Akobeng AK; Thomas AG
Cochrane Database Syst Rev; 2012 Jul; (7):CD009118. PubMed ID: 22786523
[TBL] [Abstract][Full Text] [Related]
11. Add-on fesoterodine for residual storage symptoms suggestive of overactive bladder in men receiving α-blocker treatment for lower urinary tract symptoms.
Kaplan SA; Roehrborn CG; Gong J; Sun F; Guan Z
BJU Int; 2012 Jun; 109(12):1831-40. PubMed ID: 21966995
[TBL] [Abstract][Full Text] [Related]
12. Impact of solifenacin on diary-recorded and patient-reported urgency in patients with severe overactive bladder (OAB) symptoms.
Serels SR; Toglia MR; Forero-Schwanhaeuser S; He W
Curr Med Res Opin; 2010 Oct; 26(10):2277-85. PubMed ID: 20707767
[TBL] [Abstract][Full Text] [Related]
13. Duloxetine compared with placebo for treating women with symptoms of overactive bladder.
Steers WD; Herschorn S; Kreder KJ; Moore K; Strohbehn K; Yalcin I; Bump RC;
BJU Int; 2007 Aug; 100(2):337-45. PubMed ID: 17511767
[TBL] [Abstract][Full Text] [Related]
14. A double-blind, randomized, placebo-controlled, parallel study to evaluate the efficacy and safety of imidafenacin in patients with overactive bladder in Taiwan.
Chuang YC; Lin CC; Chow PM; Lien CS; Tsui KH; Chou CL; Lee HY; Meng E; Kuo HC
Low Urin Tract Symptoms; 2021 Jan; 13(1):108-117. PubMed ID: 32844599
[TBL] [Abstract][Full Text] [Related]
15. Correlations among improvements in urgency urinary incontinence, health-related quality of life, and perception of bladder-related problems in incontinent subjects with overactive bladder treated with tolterodine or placebo.
Van Kerrebroeck PE; Kelleher CJ; Coyne KS; Kopp Z; Brodsky M; Wang JT
Health Qual Life Outcomes; 2009 Feb; 7():13. PubMed ID: 19226471
[TBL] [Abstract][Full Text] [Related]
16. Once-daily trospium chloride 60 mg extended-release provides effective, long-term relief of overactive bladder syndrome symptoms.
Zinner NR; Dmochowski RR; Staskin DR; Siami PF; Sand PK; Oefelein MG
Neurourol Urodyn; 2011 Sep; 30(7):1214-9. PubMed ID: 21462240
[TBL] [Abstract][Full Text] [Related]
17. New polyethylene glycol laxative for treatment of constipation in adults: a randomized, double-blind, placebo-controlled study.
Cleveland MV; Flavin DP; Ruben RA; Epstein RM; Clark GE
South Med J; 2001 May; 94(5):478-81. PubMed ID: 11372795
[TBL] [Abstract][Full Text] [Related]
18. Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a β(3)-adrenoceptor agonist, in overactive bladder.
Chapple CR; Kaplan SA; Mitcheson D; Klecka J; Cummings J; Drogendijk T; Dorrepaal C; Martin N
Eur Urol; 2013 Feb; 63(2):296-305. PubMed ID: 23195283
[TBL] [Abstract][Full Text] [Related]
19. Polyethylene Glycol 3350 With Electrolytes Versus Polyethylene Glycol 4000 for Constipation: A Randomized, Controlled Trial.
Bekkali NLH; Hoekman DR; Liem O; Bongers MEJ; van Wijk MP; Zegers B; Pelleboer RA; Verwijs W; Koot BGP; Voropaiev M; Benninga MA
J Pediatr Gastroenterol Nutr; 2018 Jan; 66(1):10-15. PubMed ID: 28906317
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of a neurokinin-1 receptor antagonist in postmenopausal women with overactive bladder with urge urinary incontinence.
Green SA; Alon A; Ianus J; McNaughton KS; Tozzi CA; Reiss TF
J Urol; 2006 Dec; 176(6 Pt 1):2535-40; discussion 2540. PubMed ID: 17085151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
